Connor Yap

Patent Attorney @AstraZeneca

Cambridge, GB

Responsible for independently developing and executing IP strategies for pre-clinical and clinical assets across key AZ therapeutic areas (oncology, CVRM & R&I). Experienced in the drafting, prosecution and management of complex global patent portfolios for diverse therapeutic modalities (e.g. small molecules, antibody-drug conjugates, radioconjugates & siRNA), working with R&D and other functions where appropriate to achieve robust & disruptive IP protection. I have also been involved in providing IP support for contractual matters (e.g. collaboration/license agreements) and high profile M&A transactions (such as the multi-billion dollar acquisition of Fusion Pharmaceuticals in 2024), advising the business on key risks, gaps and mitigation strategies under significant time pressure.Excellent understanding of regulatory exclusivity periods and their interplay with IP, enabling me to advise the business on projected loss of exclusivity & life cycle management strategies.

Queen Mary University of London

PGCert Intellectual Property Law

University of Nottingham

Doctor of Philosophy (PhD), Centre for Doctoral Training in Sustainable Chemistry

Queen's University Belfast

MSci, Chemistry